Instil Bio signed a $100 million at-the-market sales agreement with Jefferies, which earns 3.0 percent of gross sales. The last reported sale price before the filing was $19.36, and the lead drug's clinical data come from a partner's small Chinese trial.
Latest Instil Bio news
We have not published a story on Instil Bio yet. When there is news, it will appear here.
Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $5.5 million.
Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.
Questions about Instil Bio
Has Instil Bio raised money recently?
Our latest story on this, dated Mar 31, 2025: "Instil Bio sets up $100 million at-the-market stock sale program with Jefferies". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of Instil Bio?
Instil Bio, Inc. trades under the ticker TIL on NASDAQ.
Where is Instil Bio listed?
Instil Bio, Inc. is listed on NASDAQ.
What is the SEC CIK of Instil Bio?
The SEC Central Index Key (CIK) for Instil Bio, Inc. is 1789769. Its filings are on SEC EDGAR.
How many shares does Instil Bio have outstanding?
6,781,976 shares as of 2026-08-11, per the cover page of its 10-Q filed 2026-08-13.
Which country or territory is Instil Bio listed under?
Our directory records Instil Bio, Inc. under United States.
What does Instil Bio do?
Our directory classifies Instil Bio, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
What is the ISIN of Instil Bio?
The ISIN recorded for Instil Bio, Inc. is US45783C2008.
Does aibio.space cover Instil Bio?
aibio.space lists Instil Bio, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Instil Bio incorporated?
SEC records list its state or country of incorporation as NY.
Is Instil Bio profitable?
Instil Bio, Inc. reported a net loss of $71.4 million for the fiscal year ended Dec 31, 2025, and used $36.6 million of cash in operations, per its annual report to the SEC.
How much cash does Instil Bio have?
$5.5 million in cash at Jun 30, 2026, per its 10-Q.
What is the latest Instil Bio (TIL) stock news?
Our latest story on Instil Bio, dated Mar 31, 2025: "Instil Bio sets up $100 million at-the-market stock sale program with Jefferies". Instil Bio signed a $100 million at-the-market sales agreement with Jefferies, which earns 3.0 percent of gross sales. The last reported sale price before the filing was $19.36, and the lead drug's clinical data come from a partner's small Chinese trial. Source.
What is Instil Bio's market cap?
We do not publish live share prices. In its annual report, Instil Bio, Inc. put the market value of shares held by non-affiliates (public float) at $83.4 million as of Jun 30, 2025.
Is Instil Bio a smaller reporting company?
SEC records list Instil Bio, Inc.'s filer category as: Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company.
Investor discussion: Instil Bio
Members talk about Instil Bio (TIL). Reader posts, not aibio.space reporting, and not investment advice.
Rules
Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
Say whether you hold the stock. Every post states long, short or no position.
No paid or sponsored posts. Do not post for anyone who pays or rewards you.
No buy or sell calls and no price targets.
No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
No personal details and no spam. No links at all for your first 7 days as a member.
Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.
Capital-markets timeline
Financings, listing notices, splits, legal actions and other investor events at Instil Bio, newest first. Each line links the filing it comes from.
Legal
Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). Source
Distress
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
Distress
Reported the end of a material agreement. SEC Form 8-K (Items 1.02). Source
Reported the end of a material agreement. SEC Form 8-K (Items 1.01,1.02,2.03). Source
Stock chart
Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open NASDAQ:TIL on TradingView.
SEC filings and registration
SEC name
Instil Bio, Inc.
CIK
1789769
Industry (SIC)
Biological Products, (No Diagnostic Substances) (2836)
US tickers
TIL (Nasdaq)
State or country of incorporation
NY
Fiscal year ends
December 31
Filer category
Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Business address
3963 MAPLE AVENUE, DALLAS, TX, 75219
Phone
(972) 499-3350
Shares outstanding
6,781,976 as of 2026-08-11 (10-Q filed 2026-08-13)
Recent filings (8-K and 6-K are the company's own announcements)
Source: SEC EDGAR, retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.
Listing details
Instil Bio, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker TIL, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.
Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.
Published and maintained by aibio.space. Not investment advice. How we work.
Who manages this pageThis page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio